The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche
Travel, Accommodations, Expenses - Amgen; Takeda
Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study).
 
Giulia Pasello
Honoraria - AstraZeneca/UK; Johnson & Johnson; MSD; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca/UK; Johnson & Johnson; Lilly; MSD; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca/UK; Johnson & Johnson; Lilly; MSD; Novartis; Roche
Research Funding - MSD; Roche
 
Daniela Scattolin
No Relationships to Disclose
 
Fabiana Letizia Cecere
No Relationships to Disclose
 
Luana Calabrò
No Relationships to Disclose
 
Federica Grosso
Consulting or Advisory Role - BMSi; Deciphera; MSD; Novartis; Novocure
Speakers' Bureau - Novocure
 
Giovanni Ceresoli
No Relationships to Disclose
 
Marcello Tiseo
No Relationships to Disclose
 
Alessandra Bearz
No Relationships to Disclose
 
Paolo Zucali
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Merck Sharp & Dohme (MSD).; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Roche
 
Francesco Callegarin
No Relationships to Disclose
 
Giuseppe Marulli
No Relationships to Disclose
 
Gian Luca De Salvo
No Relationships to Disclose
 
Antonio Rosato
No Relationships to Disclose
 
Loredana Urso
No Relationships to Disclose
 
Stefano Indraccolo
No Relationships to Disclose
 
Eleonora Faccioli
No Relationships to Disclose
 
Laura Bonanno
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Johnson & Johnson; MSD; Novartis; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Roche
Research Funding - AstraZeneca
 
Fiorella Calabrese
No Relationships to Disclose
 
Federico Rea
No Relationships to Disclose
 
Valentina Guarneri
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Merck Serono; MSD; Novartis; Olema Oncology; Pierre Fabre
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini Steamline; Novartis; Roche; Zentiva
Research Funding - AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst)
Expert Testimony - Lilly
Travel, Accommodations, Expenses - AstraZeneca; Gilead/Forty Seven